Skip to Content
Merck
All Photos(1)

Key Documents

T1200000

Thiopental

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(±)-Thiopental, 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid, Pentothal

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C11H18N2O2S
CAS Number:
Molecular Weight:
242.34
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
Pricing and availability is not currently available.

API family

thiopental

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

CCCC(C)C1(CC)C(=O)NC(=S)NC1=O

InChI

1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)

InChI key

IUJDSEJGGMCXSG-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Thiopental EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Colleen K Loo et al.
Journal of affective disorders, 142(1-3), 233-240 (2012-08-04)
Preliminary evidence suggests that the use of ketamine during electroconvulsive therapy (ECT) may be neuroprotective against cognitive impairment and have synergistic antidepressant effects. This study tested whether the addition of ketamine reduced cognitive impairment and enhanced efficacy over a course
H Murdoch et al.
International journal of obstetric anesthesia, 22(1), 31-35 (2012-11-06)
A national survey of current practice and preferred drug choices for both induction and maintenance of general anaesthesia for caesarean section was undertaken. Following approval by the Obstetric Anaesthetists' Association, all UK consultant members were invited to respond to an
Ibrahim M Alharfi et al.
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 14(2), 203-209 (2013-01-15)
To determine the occurrence rate of central diabetes insipidus in pediatric patients with severe traumatic brain injury and to describe the clinical, injury, biochemical, imaging, and intervention variables associated with mortality. Retrospective chart and imaging review. Children's Hospital, level 1
Bożena Bądzyńska et al.
Pharmacological reports : PR, 66(5), 856-861 (2014-08-26)
Activation of angiotensin AT2 receptors (AT2R) counteracts vasoconstrictor effects of AT1R stimulation and contributes to blood pressure control. We examined effects on mean arterial pressure (MAP) and renal hemodynamics of LKP, a tripeptide fragment of novokinine, an established AT2R agonist.
Chadi G Abdallah et al.
The journal of ECT, 28(3), 157-161 (2012-08-01)
Studies now provide strong evidence that the N-methyl-D-aspartate receptor antagonist ketamine possesses rapidly acting antidepressant properties. This study aimed to determine if a low dose of ketamine could be used to expedite and augment the antidepressant effects of electroconvulsive therapy

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service